Navigation Links
Omeros Prices $30 Million Public Offering of Common Stock
Date:6/27/2012

SEATTLE, June 27, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 2,926,830 shares of its common stock at a price to the public of $10.25 per share for gross proceeds of $30.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses, will be approximately $28.1 million. Omeros has also granted the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover overallotments, if any, which would result in additional gross proceeds of approximately $4.5 million if exercised in full.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the clinical development of Omeros' two ongoing Phase 3 clinical development programs – OMS302 for use during intraocular lens replacement procedures and OMS103HP for use during arthroscopic partial meniscectomy surgery.  The net offering proceeds may also be used to fund research and development in Omeros' preclinical studies and clinical trials, capital expenditures, working capital and to otherwise advance Omeros' product candidates toward commercialization. The offering is expected to close on or about July 2, 2012, subject to the satisfaction of customary closing conditions.

Cowen and Company, LLC and Deutsche Bank Securities Inc. acted as the joint book-running managers for the offering, Canaccord Genuity Inc. and Wedbush PacGrow Life Sciences acted as co-managers, and WBB Securities served as a financial advisor to Omeros.

A shelf registration statement (File No. 333-169856) relating to these securities was filed with the Securities and Exchange Commission on October 8, 2010 and declared effective on October 18, 2010. A preliminary prospectus supplement related to the offering was filed with the Securities and Exchange Commission on June 26, 2012.  The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140), or Deutsche Bank Securities Inc., Attn: Prospectus Group, 60 Wall Street, New York, NY 10005-2836 or by telephone at: (800) 503-4611, or by email at: prospectus.CPDG@db.com. An electronic copy of the prospectus supplement and accompanying prospectus relating to the offering is available on the website of the Securities and Exchange Commission at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Omeros, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding Omeros' expectations regarding the underwritten public offering announced today. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2012. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Proposed Public Offering of Common Stock
2. Omeros to Present at Jefferies 2012 Global Healthcare Conference
3. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
4. Omeros to Present at Deutsche Bank Securities Health Care Conference
5. Novelos Therapeutics Prices $5.4 Million Public Offering
6. Albemarle to increase ibuprofen prices
7. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
8. Spot On Sciences Awarded $1 Million DARPA Grant to Develop a Blood Sample Collection Device
9. Developers: Deadline Approaching for Allscripts Million Hearts CDS Challenge
10. Biodel Announces $18.5 Million Private Placement
11. The Michael J. Fox Foundation Launches The $14 Million-Edmond J. Safra Core Programs for PD Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
Breaking Medicine News(10 mins):